BrickBio

About:

BrickBio is a developer of a bioconjugation platform intended for research of site-specific modification of proteins.

Website: https://www.brickbio.com/

Top Investors: Samsung Venture Investment

Description:

BrickBio is a developer of a bioconjugation platform intended for research of site-specific modification of proteins. The company's platform can optimize any conjugate with the selective modification of a number of distinct websites on a single protein through its prokaryotic and eukaryotic expression programs, thereby providing hospitals with amino acid coupled therapeutics to improve protein characteristics.

Total Funding Amount:

$5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

2019-01-01

Founders:

John Boyce

Number of Employees:

1-10

Last Funding Date:

2024-03-18

IPO Status:

Private

Industries:

© 2025 bioDAO.ai